共识分子亚型对转移性结直肠癌生存的影响:CALGB/SWOG 80405(Alliance)研究结果
CALGB/SWOG 80405 III期试验比较贝伐珠单抗或西妥昔单抗联合化疗一线治疗晚期结直肠癌,对581例患者原发肿瘤行NanoString基因表达分型。共识分子亚型(CMS)对总生存和无进展生存均有预后价值(P<.001),且与治疗交互预测生存;CMS1中贝伐珠单抗组总生存优于西妥昔单抗组,CMS2中则西妥昔单抗组优于贝伐珠单抗组。
要点
- CMS分型对转移性结直肠癌总生存和无进展生存均有高度预后价值(P<.001)。
- CMS与治疗交互预测总生存(交互P<.001)和无进展生存(交互P=.0032)。
- CMS1患者贝伐珠单抗组总生存显著长于西妥昔单抗组,CMS2患者西妥昔单抗组显著长于贝伐珠单抗组。
核心结论
- CMS分型可能具有临床实用性,完善CMS分类或有助于识别最可能从特定靶向治疗中获益的转移性结直肠癌患者。
研究设计与样本
- CALGB/SWOG 80405为III期试验,比较贝伐珠单抗或西妥昔单抗联合输注氟尿嘧啶、亚叶酸和奥沙利铂或氟尿嘧啶、亚叶酸和伊立替康一线治疗晚期结直肠癌。
- 采用新型NanoString基因表达 panel 对581例入组患者原发结直肠癌进行CMS分类,评估其预后和预测价值。
主要发现
- CMS对总生存高度预后(P<.001),对无进展生存高度预后(P<.001)。
- CMS对总生存有预测性(交互P<.001),对无进展生存有预测性(交互P=.0032)。
- CMS1队列中,贝伐珠单抗组总生存显著长于西妥昔单抗组(P<.001)。
- CMS2队列中,西妥昔单抗组总生存显著长于贝伐珠单抗组(P=.0046)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression-based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405. PATIENTS AND METHODS: CALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients. RESULTS: The CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS (P for interaction < .001) and PFS (P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab (P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab (P = .0046). CONCLUSION: These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
引用
- Lenz HJ, Ou FS, Venook AP, et al. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019. PMID: 31042420. doi:10.1200/JCO.18.02258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。